(Q48264152)

English

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

scientific article published in May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/26009229

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. (English)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/26009229

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Lawrence Blonde

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jorge Gross

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Vincent Woo

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Honghua Jiang

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jessie L Fahrbach

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Zvonko Milicevic

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

0 references

publication date

1 May 2015

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/26009229

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

385

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

9982

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

2057-2066

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26009229%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight beneficial treatments for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

General multistage gatekeeping procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960936-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48264152&oldid=1563391600"